Table 1.
Treatment | Ratio CCK9/CCK8 |
---|---|
None (control) | 1.00 ± 0.06 |
CLIK-148 | 0.49 ± 0.15* |
PC1/3 antisense | 1.58 ± 0.14* |
AtT-20 cells were treated with the specific cathepsin L inhibitor, CLIK-148 (24 hrs), or with PC1/3 antisense (by stable expression). At the end of the treatment period, secretion media was collected and subjected to HPLC analyses and CCK RIA (as shown in figure 5). The amounts of CCK8 and CCK9 were compared as ratios, with the ratio normalized to 1.00 for untreated control cells. Differences in ratios of CCK9/CCK8 were statistically significant, with p < 0.05 (by student's t-test, n = 4-6).